CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical...
Read MoreCatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to...
Read MoreCatalYm Announces Leadership Change
CatalYm Announces Leadership Change Munich, Germany, October 11, 2024 – CatalYm...
Read MoreGDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers
Sabrina Genssler, Daniel Schaetzlein, Eugen Leo, Markus Haake and Christine Schuberth-Wagner /...
Read MoreSHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells
Markus Haake, Neha Vashist, Beatrice Haack, Birgitt Fischer, Kristin Eichler, Matthias Kist,...
Read MoreCatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...
Read MoreCatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...
Read MoreCatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...
Read MoreGDF-15 contributes to proliferation and immune escape of malignant gliomas
P. Roth, M. Junker, I. Tritschler, M. Mittelbronn, Y. Dombrowski, S. N....
Read More